CTIS2024-512756-38-00招募中1 期
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment - 1425-0003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Diagnosis of CD for at least 3 months prior to visit 1, as confirmed at any time in the past by endoscopy and/OR radiology, and supported by histology., Elevated CRP (= 5 mg/L) OR elevated fecal calprotectin (= 250 µg/g), Symptomatic CD defined as = CDAI 150, Presence of mucosal ulcers in at least one segment of the ileum or colon and a SESCD score = 7 (for patients with isolated ileitis =4), Patients who are experienced to at least 1 tumor necrosis factor (TNF) antagonist at a dose approved for CD. Patients may have stopped TNF antagonist treatment due to primary or secondary non -responsiveness, intolerance, or for other reasons., May be receiving a therapeutic dose of the following: Oral 5-ASA compounds Oral corticosteroids AZA, MP, 6-TG, or MTX, Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control, Further inclusion criteria apply.
排除标准
- •Have any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to randomization and are not anticipated to require surgery. Patients with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses present based on investigator`s judgement, Presence of clinically significant acute or chronic infections not otherwise listed, including viral hepatitis, COVID-19, or others based on investigator's judgement., A marked baseline prolongation of QT/QTc interval (such as QTcF intervals that are greater than 450 ms for men, 470 ms for female) or any other relevant ECG finding at screening. Both have to be confirmed by repeated ECG recording., Further exclusion criteria apply, Have complications of CD such as strictures, stenosis, short bowel syndrome, or any other manifestation that might require surgery, or could preclude the use of SESCD/ CDAI to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with BI 706321, Patient with an IBD diagnosis other than CD, Have had any kind of bowel resection or diversion within 4 months or any other intraabdominal surgery within 3 months prior to visit 1. Patients with current ileostomy, colostomy, or ileorectal anastomosis are excluded., Treatment with: - any non-biologic medication for IBD (tacrolimus or mycophenolate mofetil, systemic corticosteroids), other than those allowed per inclusion criteria, within 30 days prior to randomization - any biologic treatment with a TNF-alpha antagonist (adalimumab, infliximab, golimumab, certolizumab pegol) or vedolizumab (or a biosimilar) within 4 weeks prior to randomization. - any previous treatment with ustekinumab (or a biosimilar of this drug) - any previous treatment with an investigational (or subsequently approved) non-biologic/biologic drug for CD (including but not limited to JAK inhibitors [e.g. upadacitinib], S1P modulators, IL-23 inhibitors [e.g. risankizumab], antiintegrins). - any investigational drug for an indication other than CD during the course of the actual study and within 30 days or 5 half-lives (whichever is longer) prior to randomisation. - any prior exposure to rituximab within 1 year prior to randomisation., Positive stool examination for C difficile (toxin A/B and GDH ag – test positive) or other intestinal pathogens <30 days prior to randomization., Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed, Increased risk of infectious complications (e.g. recent pyogenic inf, any congenital or acquired immunodeficiency (e.g. Human immunodeficiency virus), past organ or stem cell transplantation (with exception of a corneal transplant > 12 weeks prior to screening) or have ever received stem cell therapy (e.g., Prochymal). Prior treatment with a somatic cell therapy product (e.g., Alofisel) is not excluded, provided it was administered > 8 w prior to randomization BCG vaccines = 1 year prior to randomization, Live or attenuated vaccination within 4 weeks prior to randomization
研究者
相似试验
进行中（未招募）
1 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s DiseaseCrohn`s Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004527-16-PLBoehringer Ingelheim International GmbH50
进行中（未招募）
1 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s DiseaseCrohn`s Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004527-16-BEBoehringer Ingelheim International GmbH50
进行中（未招募）
1 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s DiseaseCrohn`s Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004527-16-DEBoehringer Ingelheim International GmbH50
进行中（未招募）
1 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s DiseaseCrohn`s Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004527-16-DKBoehringer Ingelheim International GmbH76
招募中
1 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s DiseaseCrohn`s Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004527-16-NLBoehringer Ingelheim International GmbH50